Jun 01,2020

Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

Flash glucose monitoring (FGM) is a factory-calibrated sensor-based technology for the measurement of interstitial glucose. A systematic review and meta-analysis to assess its efficacy and safety in patients with type 1 and type 2 diabetes was performed.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 13,2020

NEW LATE-BREAKING DATA SHOW USE OF ABBOTT'S FREESTYLE® LIBRE SYSTEM SIGNIFICANTLY REDUCES HBA1C LEVELS IN PEOPLE WITH TYPE 2 DIABETES USING INSULIN OR NOT

Abbott (NYSE: ABT) announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading continuous glucose monitoring (CGM) technology, is associated with significant reduction in hemoglobin A1c (HbA1c) levels for people living with type 2 diabetes on either long-acting insulin or non-insulin therapy. These results are similar to outcomes typically seen when adding insulin therapy to treatment regimens, indicating people may be able to manage their glucose levels with CGM technology instead of adding insulin. The real-world data were presented as a late-breaking abstract at the American Diabetes Association (ADA) 80th Scientific Sessions.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 15,2020

ABBOTT'S FREESTYLE® LIBRE 2 ICGM CLEARED IN U.S. FOR ADULTS AND CHILDREN WITH DIABETES, ACHIEVING HIGHEST LEVEL OF ACCURACY AND PERFORMANCE STANDARDS

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2 integrated continuous glucose monitoring (iCGM) system for adults and children ages 4 and older with diabetes. This is the only iCGM system with optional real-time alarms that measures glucose levels every minute, meeting the highest level of accuracy standards over 14 days, including superior day one accuracy compared to the other iCGM and excellent accuracy and alarm performance at low end glucose levels.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 15,2020

One Drop Announces Long-term Outcomes Forecasts for Diabetes-related Biomarkers and Overnight Hypoglycemia Predictions for CGM Users

One Drop, a leader in digital therapeutics solutions for people living with diabetes and other chronic conditions, presented long-term A1C, blood pressure, and weight outcomes forecasts for individuals, along with overnight hypoglycemia predictions for CGM users at the 80th Annual American Diabetes Association Virtual Scientific Sessions. New predictions lay the foundation for One Drop’s highly personalized and adaptive data-driven health products.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 16,2020

NEW DATA SHOW USE OF ABBOTT'S FREESTYLE® LIBRE SYSTEM REDUCES ALL-CAUSE, DIABETIC KETOACIDOSIS-RELATED HOSPITALIZATION RATES AND ACUTE DIABETES EVENTS

Abbott (NYSE: ABT) announced results from multiple new real-world studies that demonstrate how use of the FreeStyle Libre system, the world-leading continuous glucose monitoring (CGM) technology, can lead to significant clinical benefits among people living with type 1 and type 2 diabetes. Notable findings, presented at this year's American Diabetes Association (ADA) 80th Scientific Sessions, show that using the FreeStyle Libre technology is associated with substantial reductions in hospitalizations from diabetic ketoacidosis (DKA), a serious condition that can lead to diabetic coma or even death.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 09,2020

Medtronic and Tandem Diabetes Care Enter Into Patent Cross-License Agreement

Medtronic and Tandem Diabetes Care today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. With certain exclusions, this agreement applies to the companies’ existing products, as well as new products for at least the next five years, and also includes a provision not to clone one another’s products. No payments will be exchanged as part of this agreement and further terms were not disclosed.

COLLABORATION PARTNERSHIP

#product & service

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 23,2020

Nemaura Medical to Integrate Activity Data From Third Party Wearable Devices to Its proBEAT™ App

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), today announced that it has commissioned the integration of data from third party wearable devices into its proBEAT™ app which is planned for launch in the USA later this year.

PRODUCT

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 10,2020

PHC Holdings Corporation And Ascensia Diabetes Care Announce Financing Agreement And Exclusive Global Commercial Agreement With Senseonics

PHC Holdings Corporation and Ascensia Diabetes Care, a PHC Group company, today announced a strategic partnership with Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. The partnership comprises a global commercialization and distribution agreement and a concurrent financing agreement.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 19,2020

Nemaura Medical issues Presentation Pertaining to the use of Continuous Glucose Monitoring in COVID-19 Patients

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today issued a presentation outlining how CGM is being used by quarantined and hospitalised COVID-19 patients.

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 27,2020

Tandem Diabetes Care Announces NEJM Publication of Pediatric Study Demonstrating Increased Time-In-Range using the t:slim X2 Insulin Pump with Control-IQ Technology

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by the New England Journal of Medicine (NEJM) of results from the Protocol 5 study (DCLP5) of the International Diabetes Closed Loop (iDCL) trial. Results demonstrated increased time spent in range (70-180 mg/dL) in children ages 6 to 13 years old using the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology.

CLINICAL STUDY

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM